Elucid Vivo provides clinical solutions based on histology and machine learning. We provide solutions for lipid rich necrotic core, atherosclerotic plaque, CTA plaque analysis, risk of heart attack and stroke.
Total raised: $27M
Funding Rounds 1
| Date | Series | Amount | Investors | Deal News |
| 22.06.2022 | Series B | $27M | - | - |